Guohai H. Su

No. 105, Jiefang Road, 
Jinan, CN 
No. 105, Jiefang Road, 
Jinan, CN 

Overview

Guohai Su practices practicing medicine in Jinan, China.

Their clinical expertise encompasses Heart Attack, Acute Coronary Syndrome, Atherosclerosis, High Cholesterol, and Percutaneous Coronary Intervention (PCI).

They are actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 3 clinical trials.

Locations

No. 105, Jiefang Road, Jinan, 250013, China
Other Locations
6699 Qingdao Road, Jinan, 250117, China
Union Hospital, Wuhan, 430022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Recombinant Human Neuregulin for Injection
Study Phase: Phase 3
View 1 Less Clinical Trial

91 Total Publications

Risk Prediction of Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention Using Inflammatory Biomarkers.
Risk Prediction of Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention Using Inflammatory Biomarkers.
Journal: Journal of visualized experiments : JoVE
Published: July 06, 2026

Frequently Asked Questions about Guohai H. Su

Is Guohai H. Su a top-rated expert for Heart Attack?

MediFind is an objective health platform that identifies experts based on real-world data. Guohai H. Su is classified as an Experienced expert for Heart Attack, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Guohai H. Su participate in research or clinical trials?

Yes. Guohai H. Su has published 91 articles and abstracts on conditions like Heart Attack. You can view a list of Guohai H. Su's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Su's expertise for a condition
ConditionClose
        View All 14 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile